BERLIN–(COMMERCIAL THREAD) – Regulatory news:
NOXXON Pharma SA (Euronext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), announces that new data from the ongoing GLORIA Phase I / II trial in brain cancer will be presented by the Dr. Frank Giordano, principal investigator of the study, in an oral presentation at the annual meeting of the Society for Neuro-Oncology. The meeting will take place in Boston, Massachusetts, United States, from November 18-21, 2021.
The details of the oral presentation are as follows:
Title: CXCL12 Inhibition in Unmethylated MGMT Glioblastoma – Results of an Early Proof of Concept Assessment in the Multicenter Phase I / II GLORIA Trial (NCT04121455)
Session title: Summary of the session: Clinical trials I
Date of the session: Friday, November 19, 2021
Presentation time: 5:00 p.m. – 5:05 p.m. EST / 11:00 a.m. – 11:05 p.m. CET
Presenter: Dr Frank Giordano, Director and Chairman of the Radiation Oncology Department at the University Hospital Bonn, Germany
The embargo for abstracts published in the 2021 Abstracts Supplement of the official journal SNO Neuro-Oncology will be lifted at 7:00 a.m. EST on Thursday, November 11, 2021 and the abstract will be available at: https://academic.oup.com / neuroncology.
To register for the event, please click here.
A copy of the presentation will be available on the NOXXON website shortly after the event.
NOXXON’s oncology-focused pipeline acts on the tumor microenvironment (TME) and the cancer immunity cycle by breaking down the tumor protective barrier and blocking tumor repair. By neutralizing the chemokines in TME, NOXXON’s approach works in combination with other forms of treatment to weaken tumor defenses against the immune system and allow greater therapeutic impact. NOXXON’s main program, NOX-A12, provided the final revenue data of a Keytruda® combined trial in patients with metastatic colorectal and pancreatic cancer published at the ESMO conference in September 2020 and July 2021, the company announced its phase 2 study, OPTIMUS, to further assess safety and efficacy NOX-A12 in combination with Keytruda from Merck® and two different chemotherapy regimens as second-line treatment in patients with metastatic pancreatic cancer. NOXXON is also studying NOX-A12 in brain cancer in combination with radiation therapy, which has been granted orphan drug status in the US and EU for the treatment of certain brain cancers. GLORIA, a trial of NOX-A12 in combination with radiation therapy in patients with newly diagnosed brain cancer who will not clinically benefit from standard chemotherapy, provided interim data from the first two cohorts showing consistent tumor reductions and objective tumor responses. The company’s second clinical-stage active, NOX-E36, is a phase 2 TME active targeting the innate immune system. NOXXON plans to test NOX-E36 in patients with solid tumors. More information is available at: www.noxxon.com.
Keytruda® is a registered trademark of Merck Sharp & Dohme Corp
Visit NOXXON on LinkedIn and Twitter
About the GLORIA study
GLORIA (NCT04121455) is the phase 1/2 dose escalation study of NOXXON of NOX-A12 in combination with irradiation in patients with first-line glioblastoma (brain cancer) with a non-MGMT promoter. methylated (resistant to standard chemotherapy).
About the OPTIMUS study
OPTIMUS (NCT04901741) is NOXXON’s open-label, two-arm phase 2 study of NOX-A12 in combination with pembrolizumab and nanoliposomal irinotecan / 5-FU / leucovorin or gemcitabine / nab-paclitaxel in patients with ‘stable microsatellite metastatic pancreatic cancer.
Certain statements in this communication contain wording or terms that refer to future or future developments, as well as negations of such wordings or terms, or similar terminology. These are described as forward-looking statements. In addition, all information contained in this communication concerning the expected or future results of the business segments, financial indicators, changes in the financial situation or other financial or statistical data contains such forward-looking statements. The company cautions potential investors not to rely on such forward-looking statements as certain predictions of actual future events and developments. The company is neither responsible nor liable for updating this information, which only represents the inventory on the day of publication.